Retrovirus-mediated transfer of anti-MDR1 hammerhead ribozymes into multidrug-resistant human leukemia cells: Screening for effective target sites

International Journal of Cancer

Volumn 81, Issue 6, 1999, Pages 944-950

  Kobayashi, Hiroyuki ^a,b   Takemura, Yuzuru ^b   Wang, Fu Sheng ^c   Oka, Tetsuo ^a   Ohnuma, Takao ^c  

^a TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ACTIN; GLYCOPROTEIN P; RIBOZYME; RNA POLYMERASE; TRIMETREXATE; VINCRISTINE; VIRUS VECTOR;

ARTICLE; CANCER RESISTANCE; CONTROLLED STUDY; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; LEUKEMIA CELL; LEUKEMIA CELL LINE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROMOTER REGION; RETROVIRUS;

BASE SEQUENCE; CLONING, MOLECULAR; COCULTURE TECHNIQUES; DRUG RESISTANCE, MULTIPLE; EXONS; HUMANS; INTRONS; LEUKEMIA, LYMPHOCYTIC, ACUTE; MOLECULAR SEQUENCE DATA; OLIGODEOXYRIBONUCLEOTIDES; P-GLYCOPROTEIN; PROMOTER REGIONS (GENETICS); RECOMBINANT PROTEINS; RNA POLYMERASE III; RNA, CATALYTIC; TRANSCRIPTION, GENETIC; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0032969903     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19990611)81:6<944::AID-IJC17>3.0.CO;2-Y     Document Type: Article

References (31)

1. met gene. Nucleic Acids Res., 12, 1101-1115 (1984).
2. ARKIN, H., OHNUMA, T., KAMEN, B.A., HOLLAND, J.F. and VALLABHAJOSULA, S., Multidrug resistance in a human leukemic cell line selected for resistance to trimetrexate. Cancer Res., 49, 6556-6561 (1989).
3. COTTEN, M. and BIRNSTIEL, M.L., Ribozyme mediated destruction of RNA in vivo. EMBO J., 8, 3861-3866 (1989).
4. ENDICOTT, J.A. and LING, V., The biochemistry of P-glycoprotein-mediated multidrug resistance. Ann. Rev. Biochem., 58, 137-171 (1989).
5. HANTZOPOULOS, P.A., SULLENGER, B.A., UNGERS, G. and GILBOA, E., Improved gene expression upon transfer of the adenosine deaminase minigene outside the transcriptional unit of a retroviral vector. Proc. nat. Acad. Sci. (Wash.), 86, 3519-3523 (1989).
6. HASELOFF, J. and GERLACH, W.J., Simple RNA enzymes with new and highly specific endoribonuclease activities. Nature (Lond.), 334, 585-591 (1988).
7. HERSCHLAG, D., Implications of ribozyme kinetics for targeting the cleavage of specific RNA molecules in vivo: more isn't always better. Proc. nat. Acad Sci. (Wash.), 88, 6921-6925 (1991).
8. HO, S.P., BRITTON, D.H., STONE, B.A., BEHRENS, D.L., LEFFET, L.M., HOBBS, F.W., MILLER, J.A. and TARINOR, G.L., Potent antisense oligonucleotides to the human multidrug resistance-1 mRNA are rationally selected by mapping RNA-accessible sites with oligonucleotide libraries. Nucleic Acids Res., 24, 1901-1907 (1996).
9. HOLM, P.S., SCANLON, K.J. and DIETEL, M., Reversal of multidrug resistance in the P-glycoprotein-positive human pancreatic cell line (EPP85-181RDB) by introduction of a hammerhead ribozyme. Brit. J. Cancer, 70, 239-243 (1994).
10. JAEGER, J.A., TURNER, D.H. and ZUKER, M., Predicting optimal and suboptimal secondary structure for RNA. Methods Enzymol., 183, 281-306 (1990).
11. KOBAYASHI, H., DORAI, T., HOLLAND, J.F. and OHNUMA, T., Reversal of drug sensitivity in multidrug-resistant tumor cells by an MDR1 (PGY1) ribozyme. Cancer Res., 54, 1271-1275 (1994).
12. KOBAYASHI, H., TAKEMURA, Y., MIYACHI, H., KAWABATA, M., MORI, S., KAWAI, Y., FURIHATA, K., SEKIGUCHI, S. and WATANABE, K., Quantitative analysis of human multidrug resistance 1 (MDR1) gene expression by nonisotopic competitive reverse transcriptase polymerase chain reaction assay. J. clin. Lab. Anal., 11, 258-266 (1997).
13. KOBAYASHI, H., TAKEMURA, Y. and OHNUMA, T., Relationship between tumor cell density and drug concentration and the cytotoxic effects of doxorubicin or vincristine: mechanism of inoculum effects. Cancer Chemother. Pharmacol., 31, 6-10 (1992).
14. KRONENWETT, R., HAAS, R. and SCZAKIEL, G., Kinetic selectivity of complementary nucleic acids: bcr-abl-directed antisense RNA and ribozymes. J. mol. Biol., 259, 632-644 (1996).
15. LI, X.-K., KOBAYASHI, H., HOLLAND, J.F. and OHNUMA, T., Expression of dihydrofolate reductase and multidrug resistance genes in trimetrexate-resistant human leukemia cell lines. Leukemia Res., 17, 483-490 (1993).
16. LIMA, W.F., BROWN-DRIVER, V., FOX, M., HANECAK, R. and BRUICE, T.W., Combinatorial screening and rational optimization for hybridization to folded hepatitis C virus RNA of oligonucleotides with biological antisense activity. J. biol. Chem., 272, 626-638 (1997).
17. MARKOWITZ, D., GOFF, S. and BANK, A., Construction and use of a safe and efficient amphotropic packaging cell line. Virology, 167, 400-406 (1988).
18. MINOWADA, J., OHNUMA, T. and MOORE, G.E., Rosette-forming human lymphoid cell lines: I. Establishment and evidence for origin of thymus-derived lymphocytes. J nat. Cancer Inst., 49, 891-895 (1972).
19. PASTAN, I., GOTTESMAN, M.M., UEDA, K., LOVELACE, E., RUTHERFORD, A. V. and WILLINGHMAN, M.C., A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. Proc. nat. Acad. Sci. (Wash.), 85, 4486-4490 (1988).
20. PERRIMAN, R., DELVES, A. and GERLACH, W.L., Extended target-site specificity for a hammerhead ribozyme. Gene, 113, 157-163 (1992).
21. RIVOLTINI, L., COLOMBO, M.P., SUPINO, R., BALLINARI, D., TSURUO, T. and PARMIANI, G., Modulation of multidrug resistance by verapamil or mdr1 anti-sense oligonucleotide does not change the high susceptibility to lymphokine-activated killing in mdr-resistant human carcinoma (LoVo) line. Int. J. Cancer, 46, 727-732 (1990).
22. SCANLON, K.J., ISHIDA, H. and KASHANI-SABET, M., Ribozyme-mediated reversal of the multidrug-resistant phenotype. Proc. nat. Acad. Sci. (Wash.), 91, 11123-11127 (1994).
23. SULLENGER, B.A., LEE, T.C., SMITH, C.A., UNGERS, G.E. and GILBOA, E., Expression of chimeric tRNA-driven antisense transcripts renders NIH3T3 cells highly resistant to moloney murine leukemia virus replication. Mol. Cell Biol., 10, 6512-6523 (1990).
24. SULLIVAN, S.M., Development of ribozymes for gene therapy. J. invest. Dermatol., 103, 85S-89S (1994).
25. THOMPSON, J.D., AYERS, D.F., MALMSTROM, T.A., MCKENZIE, T.L., GANOUSIS, L., CHOWRIRA, B.M., COUTURE, L. and STINCHCOMB, D.T., Improved accumulation and activity of ribozymes expressed from a tRNA-based RNA polymerase III promoter. Nucleic Acids Res., 23, 2259-2268 (1995).
26. met by point mutagenesis. Cell, 43, 415-422 (1985).
27. TU, G.C., CAO, Q.N., ZHOU, F. and ISRAEL, Y., Tetranucleotide GGGA motif in primary RNA transcripts. Novel target site for antisense design. J. biol. Chem., 273, 25125-25131 (1998).
28. WANG, F.S., KOBAYASHI, H., LIANG, K.W., HOLLAND, J.F. and OHNUMA, T., Retrovirus-mediated anti-MDR1 ribozymes fully restore chemosensitivity of P-glycoprotein-expressing human lymphoma cells. Hum. Gene Ther. (1999). (In press).
29. YUYAMA, N., OHKAWA, J., INOKUCHI, Y., SHIRAI, M., SATO, A., NISHIKAWA, S. and TAIRA, K., Construction of a tRNA-embedded-ribozyme trimming plasmid. Biochem. Biophys. Res. Comm., 186, 1271-1279 (1992).
30. met. Nature, 300, 81-84 (1982).
31. ZUCKER, M., Computer prediction of RNA structure. Methods Enzymol., 180, 262-288 (1989).